NCT00953823

Brief Summary

Patients with heart failure are at an increased risk for thiamin deficiency (TD), for many reasons such as malnutrition and the use of diuretic drugs. Thiamin is a B vitamin that plays an important role in the production of energy in body. Therefore, low levels of thiamin may limit the amount of energy available for the heart to pump blood. Recent thiamin supplementation trials have demonstrated significant improvements in heart function. However, while clinically important, the results of these studies are limited by their small sample sizes, indirect measurement of thiamin status and reliance on hospitalized patients. Therefore, the investigators' goal is to determine the prevalence of thiamin deficiency in ambulatory patients with heart failure by direct measurement of thiamin in red blood cells.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
110

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2009

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2009

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

August 4, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 6, 2009

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2012

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
Last Updated

December 24, 2012

Status Verified

December 1, 2012

Enrollment Period

3.5 years

First QC Date

August 4, 2009

Last Update Submit

December 21, 2012

Conditions

Keywords

Thiamin supplementationThiamin deficiencyHeart failureHeart functionVitamin B1 supplementation

Outcome Measures

Primary Outcomes (1)

  • Prevalence of Thiamin deficiency as determined by Erythrocyte thiamin pyrophosphate (TPP) measured using a direct HPLC technique

    baseline

Secondary Outcomes (3)

  • Eligible patients will be randomized to one of three commercially available doses of oral thiamin hydrochloride; 50 mg QD, 50 mg BID and 100 mg BID. They will take the supplements for 2 weeks.

    baseline to after two weeks of supplementation

  • Plasma samples will be analyzed for the plasma levels of NE, BNP, F2-isoprostanes

    baseline and after supplementation

  • Urinary excretion of thiamin following the 2 week supplementation period.

    by the end of two-week supplementation period

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Cardiology Clinic (St Michael's Hospital)

You may qualify if:

  • Patients with the primary diagnosis of ischemic, dilated, idiopathic or valvular HF characterized by an ejection fraction of \< 45% (echocardiography or radionuclide scan)
  • Patients with NYHA class I-IV symptoms

You may not qualify if:

  • Patients who are unable or unwilling to provide informed consent
  • Patients with any concurrent condition which would result in TD, namely, gastrointestinal disorders (Crohn's disease, ulcerative colitis), liver disease, prolonged diarrhoeal disease, dialysis, prolonged fever, infection or renal failure
  • Patients who are rapidly deteriorating, who are not on a stable medication regimen (≥ 2 months) or have been hospitalized for acute decompensated HF in the last 2 months
  • Patients who are on experimental medications
  • Patients who consume excessive alcohol (\> 3 drinks per day), have a documented history of alcoholism or have documented alcoholic cardiomyopathy
  • Patients who are pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St. Michael's Hospital

Toronto, Ontario, Canada

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood test

MeSH Terms

Conditions

Heart FailureBeriberi

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesThiamine DeficiencyVitamin B DeficiencyAvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Study Officials

  • Mary Keith, PhD, RD

    Unity Health Toronto

    PRINCIPAL INVESTIGATOR
  • Andrew Yan, MD

    Cardiologist, St. Michael's Hospital

    PRINCIPAL INVESTIGATOR
  • Abdul Al-Hesayen, MD

    Cardiologist, St. Michael's Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Coordinator of Nutrition and Dietetic Education/Research

Study Record Dates

First Submitted

August 4, 2009

First Posted

August 6, 2009

Study Start

May 1, 2009

Primary Completion

November 1, 2012

Study Completion

December 1, 2012

Last Updated

December 24, 2012

Record last verified: 2012-12

Locations